Skip to main content

Table 4 Tumor response by prior regimen in patients treated as second-line

From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Tumor Response Prior regimen (N = 20)
  IP FP DP NP
Complete response 0 0 0 1
Partial response 4 2 1 2
Stable disease 1 1 2 1
Progressive disease 2 0 3 0
Total 7 3 6 4
  1. Abbreviations: IP, Irinotecan/cisplatin; FP, 5-fluorouracil/cisplatin; DP, docetaxel/cisplatin; NP, vinorelbine/cisplatin.